ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
65 announcements
Alembic Pharmaceuticals received final USFDA approval for Haloperidol Tablets used in treating psychotic and Tourette’s disorders. This strengthens the company's generic portfolio in the US market.
Alembic Pharmaceuticals announced record dates for the maturity of Commercial Papers totaling ₹250 Crore. This disclosure confirms upcoming debt repayments and maintains financial transparency.
Alembic Pharmaceuticals announced that Atul Suri and Prag Goel ceased being Senior Management Personnel following an internal reporting restructure. This administrative shift streamlines the company's India business reporting.
Alembic Pharmaceuticals appointed Mr. Ramesh Juneja as Executive Vice President and Senior Management Personnel. He brings three decades of pharmaceutical sales and marketing experience.
Alembic Pharmaceuticals successfully redeemed Commercial Papers worth ₹150 Crore on their maturity date of May 29, 2026. This reflects disciplined debt management and liquidity.
Alembic Pharmaceuticals received USFDA final approval for Levothyroxine Sodium Tablets USP. The market size is estimated at ₹17942.4 Crore, strengthening the company's US generic portfolio.
Alembic Pharma delivered Q4 FY26 revenue of ₹1,838 Cr (up 4% YoY) and PAT of ₹203 Cr. FY26 revenue grew 10% YoY to ₹6,201 Cr with 25% EBITDA margins before R&D.
Management showcases a 100-year legacy transitioning into a high-tech global pharmaceutical player through massive facility expansion and R&D focus.
Alembic Pharma reported Q4FY26 revenue of INR 18.48 Bn, up 4% YoY, and PAT of INR 2.03 Bn, up 29% YoY. The company launched its first branded product, Pivya, in the US.
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹1,848 Cr (+4.4% YoY) and net profit of ₹202.7 Cr (+29.2% YoY) for Q4 FY26.
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹1,848 Cr (+4.4% YoY) and net profit of ₹201.5 Cr (+28.7% YoY) for Q4 FY26.
Mr. Rohit Garg resigned as Senior Vice President at Alembic Pharmaceuticals effective May 14, 2026. His departure for personal reasons marks a change in senior management.
Alembic Pharmaceuticals received an Establishment Inspection Report from the USFDA for its Karakhadi injectable facility. The successful inspection conclusion supports continued operational compliance at the site.
Alembic Pharmaceuticals received USFDA tentative approval for Darolutamide Tablets, targeting a ₹29,972.5 Crore market. This approval strengthens the company's oncology portfolio and international growth prospects.
Alembic Pharmaceuticals submitted its Annual Secretarial Compliance Report for the year ended March 2026. The auditor confirmed full regulatory compliance with no deviations or fines reported.
Alembic Pharmaceuticals Limited redeemed Commercial Papers worth ₹150 Crore on their maturity date. This successful repayment demonstrates the company's strong liquidity and financial discipline.
Mr. Goldee Pardesi has resigned as Associate Vice President - Sales & Marketing at Alembic Pharmaceuticals Limited, effective May 5, 2026. He is leaving to pursue new professional challenges and personal goals. The company has formally disclosed this cessation of senior management personnel to the exchanges.
Mr. Goldee Pardesi has resigned as Associate Vice President - Sales & Marketing at Alembic Pharmaceuticals Limited, effective May 5, 2026. He is leaving to pursue new professional challenges and personal goals. The company reported this cessation under the Senior Management Personnel category.
Alembic Pharmaceuticals Limited announced the resignation of Mr. Goldee Pardesi, Associate Vice President – Sales & Marketing. He was relieved from his duties effective close of business hours on May 4, 2026, to pursue other professional opportunities. The departure is part of a standard senior management transition.
Alembic Pharmaceuticals Limited has appointed Mr. Amit Nayak as Vice President - Commercial Excellence, effective May 1, 2026. Mr. Nayak brings 12 years of experience from firms including Cipla and EY. He will lead commercial excellence initiatives through digital enablement and optimized sales operations.
Alembic Pharmaceuticals Limited has appointed Mr. Amit Nayak as Vice President - Commercial Excellence, effective May 1, 2026. Mr. Nayak brings 12 years of experience from firms like Cipla and EY. He will lead commercial excellence through optimized sales operations and digital enablement.
Alembic Pharmaceuticals has designated Mr. Amit Nayak, Vice President - Commercial Excellence, as Senior Management Personnel effective May 1, 2026. Mr. Nayak brings 12 years of experience from firms including J B Chemicals, Cipla, and EY. This designation aligns with SEBI listing regulations regarding senior management disclosures.
Alembic Pharmaceuticals Ltd has scheduled a Board Meeting on May 15, 2026. The board will consider and approve audited financial results for the quarter and year ended March 31, 2026, and recommend a dividend. The trading window remains closed until 48 hours after the results declaration.
Alembic Pharmaceuticals Limited announced the demise of Mr. Saibal Mukherjee, Resident Director (General Manager - Corporate Relations), on April 26, 2026. Mr. Mukherjee was a Senior Management Personnel based at the company's Delhi office.
Alembic Pharmaceuticals Limited announced the sad demise of Mr. Saibal Mukherjee, Resident Director (Delhi Office), on April 26, 2026. Mr. Mukherjee joined the company in 2014 and was an integral part of the senior management team. The company expressed deep condolences to his family for this irreparable loss.
Alembic Pharmaceuticals received USFDA final approval for Fingolimod Capsules, 0.5 mg, used for treating relapsing forms of multiple sclerosis. The product has an estimated annual market size of approximately ₹1363.0 Crore (US$ 145 million). This marks the company's 237th cumulative ANDA approval, strengthening its US generic portfolio.
Alembic Pharmaceuticals Limited has incorporated a new wholly-owned subsidiary, Alembic Pharmaceuticals GmbH, in Germany. The company invested EUR 25,000 (₹0.27 Crore) to establish this entity, which will promote and distribute pharmaceutical products in the region.
Alembic Pharmaceuticals Limited has incorporated a wholly owned subsidiary, Alembic Pharmaceuticals GmbH, in Germany with a share capital of EUR 25,000 (₹0.27 Crore). The new entity will explore business opportunities and promote, sell, and distribute the company's pharmaceutical products in the German market.
Alembic Pharmaceuticals Limited has incorporated a new subsidiary, Alembic Lifesciences Philippines Inc., in the Philippines. The company invested ₹2.00 Crore (12 million Philippine Pesos) for a 99.99% stake to promote and distribute pharmaceutical products in the region.
Alembic Pharmaceuticals Limited incorporated a new subsidiary, Alembic Lifesciences Philippines Inc., in the Philippines. The company invested 12 million Philippine Pesos (₹1.85 Crore) for a 99.99% stake to promote and distribute pharmaceutical products in the region. This expansion marks a strategic entry into the Philippines market.